Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera

Arthritis and Rheumatism

Volumn 42, Issue 5, 1999, Pages 871-881

  Vakkalanka, Radha Krishna ^a   Woo, Caroline ^a   Kirou, Kyriakos A ^a   Koshy, Mary ^a   Berger, Douglas ^a   Crow, Mary K ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGENS, CD40; ANTIGENS, SURFACE; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CD40 LIGAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; MOLECULAR WEIGHT; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 0032940010     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199905)42:5<871::AID-ANR5>3.0.CO;2-J     Document Type: Article

References (81)

1. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact dependent B cell differentiation. J Exp Med 1992;175:1091-101.
2. Hollenbaugh D, Grosmire I, Kullas C, Chalupny N, Braesch-Andersen S, Noelle R, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell costimulatory activity. EMBO J 1992;11:4314-21.
3. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176:1543-50.
4. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
5. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles: roles of T-B activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol 1992; 149:3817-26.
6. Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/ CD18 (LFA-1)-mediated adhesion in B cells. J Immunol 1991;146: 1722-9.
7. Saeland S, Duvert V, Moreau I, Banchereau J. Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 1993;178:113-20.
8. Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E, et al. T lymphocyte T cell-B cell-activating molecule/ CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666-74.
9. Shapira SK, Vercelli D, Jabara HH, Fu SM, Geha RS. Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med 1992;175:289-92.
10. Splawski JB, Fu SM, Lipsky PE. Immunoregulatory role of CD40 in human B cell differentiation. J Immunol 1993;150:1276-85.
11. Grabstein KH, Maliszexshi CR, Shanebeck K, Sato TA, Spriggs MK, Fanslow WC, et al. The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2. J Immunol 1993;150:3141-7.
12. Nonoyama S, Hollenbaugh D, Aruffo A, Ledbetter JA, Ochs HD. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med 1993;178:1097-102.
13. Garrone P, Galibert L, Rousset F, Fu SM, Banchereau J. Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. J Immunol 1994;152:4282-90.
14. Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, et al. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994;152: 2163-71.
15. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37.
16. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Natl Med 1996;2:317-22.
17. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993;177:1209-13.
18. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995;25:1749-54.
19. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, et al. A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995;3:1031-9.
20. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, et al. Recombinant soluble CD40 ligand is biologically active. J Biol Chem 1995;270:7025-8.
21. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubrey JP, Elson G, Edgerton MD, et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996;271: 5965-7.
22. Pietravalle F, Lecoanet-Henchoz S, Aubry JP, Elson G, Bonnefoy JY, Gauchat JF. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur J Immunol 1996;26:725-8.
23. Burlinson EL, Graber P, Bonnefoy JY, Ozanne BW, Cushley W. Soluble CD40 ligand induces expression of CD25 and CD23 in resting human tonsillar B lymphocytes. Eur J Immunol 1996;26: 1069-73.
24. Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukemia. Br J Haematol 1998;100:135-41.
25. Jumper MD, Nishioka Y, Davis LS, Lipsky PE, Meek C. Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J Immunol 1995;155:2369-78.
26. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-25.
27. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
28. Feldman M, Brennan FM, Elliott M, Katsikis P, Maini RN. TNFα as a therapeutic target in rheumatoid arthritis. Circ Shock 1994; 43:179-84.
29. Hardin JA. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1986;29:457-60.
30. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
31. Crow MK, DelGiudice-Asch G, Zehetbauer JB, Lawson JL, Brot N, Weissbach H, et al. Autoantigen-specific T cell proliferation induced by the ribosoramal P2 protein in patients with systemic lupus erythematosus. J Clin Invest 1994;94:345-52.
32. Desai A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995;95:531-41.
33. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
34. Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40 mediated signals. J Exp Med 1995;182: 1857-64.
35. Karmann K, Hughes CCW, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecules expression. Proc Natl Acad Sci U S A 1995;92:4342-6.
36. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sei U S A 1997;94:1931-6.
37. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97: 2063-73.
38. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
39. Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol 1995; 155:3329-37.
40. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem 1997;272:911-5.
41. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
42. Schattner E, Elkon KB, Tumang J, Crow MK, Friedman SM. Signaling through the B cell antigen CD40 induces Apo-1 expression on human B lymphocytes and facilitates malignant B cell death. J Exp Med 1995;182:1557-65.
43. Schattner EJ, Mascarenhas J, Bishop J, Yoo D-H, Chadburn A, Crow MK, et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996;88:1375-82.
44. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
45. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361:539-41.
46. DeSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-3.
47. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72:291-300.
48. Ramesh N, Fuleihan R, Ramesh V, Lederman S, Yellin MJ, Sharma S, et al. Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol 1993;5:769-73.
49. Conley ME, Larche M, Bonagura VR, Lawton AR III, Buckley RH, Fu SM, et al. Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J Clin Invest 1994;94:1404-9.
50. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen FS, Chatila T, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 1993;90:2170-3.
51. Groux H, Torpier G, Monte D, Mouton Y, Capon A, Ameisen JC. Activation-induced cell death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331-40.
52. Kurane I, Innes BL, Hoke CH Jr, Eckels KH, Meager A, Janus J, et al. T cell activation in vivo by dengue virus infection. J Lab Clin Immunol 1995;46:35-40.
53. Lynne JE, Schmid I, Matud JL, Hirji K, Buessow S, Shilan DM, et al. Major expansions of select CD8+ subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998;177:1083-7.
54. Jarrett MP, Grayzel AI. The effect of serum from patients with systemic lupus erythematosus on the immune response of normal lymphocytes. J Rheumatol 1985;12:81-6.
55. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993;36:1098-102.
56. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993;36:519-27.
57. Pino-Otin MR, Vinas O, de la Fuente MA, Juan M, Font J, Torradeflot M, et al. Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation: present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients. J Immunol 1995;154:3015-24.
58. Martin S, Pieckmann P, Melchers I, Wagner R, Bertrams J, Voskuyl AE, et al. Circulating forms of ICAM-3 (cICAM-3): elevated levels in autoimmune diseases and lack of association with cICAM-1. J Immunol 1995;154:1951-5.
59. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Buotin B, Yarchoan R, et al. Soluble interleukin receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135: 3172-7.
60. Van Lier RA, Borst J, Vroom TM, Klein H, Mourik PV, Zeijlemaker WP, et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol 1987;139:1589-96.
61. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. The CD40 ligand expressed by human B cells stimulates B cell responses. J Immunol 1995;154:4996-5010.
62. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
63. Rothstein TL, Wang JK, Panka DJ, Foote LC, Wang Z, Stanger B, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995;374:163-5.
64. Schattner EJ, Mascarenhas J, Reyfman I, Koshy M, Woo C, Friedman SM, et al. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998;91:2689-97.
65. Gary AHM, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol 1992;149:775-82.
66. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993;178:669-74.
67. Yellin MJ, Winikoff S, Fortune SM, Crow MK, Lederman S, Chess L. Ligation of CD40 on fibroblasts induces CD54 upregulation and proliferation. J Leukoc Biol 1995;58:1-8.
68. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol 1996;156: 3932-8.
69. Harris EN, Bos K. An acute disseminated coagulopathy -vasculopathy associated with the antiphospholipid syndrome. Arch Intern Med 1991;151:231-3.
70. Farhey Y, Hess EV. Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997;6:572-7.
71. Wiley JA, Geha R, Harmsen AG. Exogenous CD40 ligand induces a pulmonary inflammation response. J Immunol 1997;158:2932-8.
72. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328-30.
73. Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD. Antibody to ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994;94:1333-8.
74. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-80.
75. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black X New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
76. Green KA, Crassi KM, Laman JD, Schoneveld A, Strawbridge RR, Foy TM, et al. Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice. J Virol 1996;70:2569-75.
77. Larsen CP, Alexander DJ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, et al. CD40-gp39 interactions play a critical role during allograft refection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996;61:4-9.
78. Carayanniotis G, Masters SR, Noelle RJ. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997;90:421-6.
79. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997;158:29-39.
80. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159:4620-7.
81. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160:2158-65.